Cefadroxil
- Generic Name
- Cefadroxil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O5S
- CAS Number
- 50370-12-2
- Unique Ingredient Identifier
- Q525PA8JJB
- Background
Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
- Indication
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
- Associated Conditions
- Bacterial Infections, Infection and inflammatory reaction due to internal prosthetic device, implant, and graft, Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Tonsillitis streptococcal, Urinary Tract Infection
- Associated Therapies
- -
Or v IV Antibiotics for Infection
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Rothman Institute Orthopaedics
- Target Recruit Count
- 308
- Registration Number
- NCT04723940
- Locations
- 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4618
- Registration Number
- NCT04297592
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 17
- Registration Number
- NCT03802552
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 199
- Registration Number
- NCT02814916
- Locations
- 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria
A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Genuine Research Center, Egypt
- Target Recruit Count
- 24
- Registration Number
- NCT02479867
- Locations
- 🇪🇬
Genuine Research Center GRC, Cairo, Egypt
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 58
- Registration Number
- NCT02381470
- Locations
- 🇵🇭
Tropical Disease Foundation, Makati City, Philippines
🇵🇭De La Salle Health Institute, Cavite, Philippines
🇸🇬National University Hospital, Singapore, Singapore, Singapore
Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Karlstad University
- Target Recruit Count
- 210
- Registration Number
- NCT00405158
- Locations
- 🇸🇪
Dept Obstetrics & Gynecology, Helsingborg Hospital, Helsingborg, Skane, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.